A Phase 1, Open Label, Fixed Sequence, Crossover Study to Investigate the Effect of BAY 2927088 on the Pharmacokinetics of Dabigatran Etexilate or Rosuvastatin in Healthy Participants
Latest Information Update: 25 Apr 2024
At a glance
- Drugs BAY 2927088 (Primary) ; Dabigatran etexilate (Primary) ; Rosuvastatin (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Bayer
- 25 Apr 2024 Last checked against:ClinicalTrials.gov: US National Institutes of Health
- 18 Apr 2024 Status changed from not yet recruiting to recruiting.
- 28 Mar 2024 New trial record